Clinical data | |
---|---|
Trade names | Mebaral, generics |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a605022 |
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 70–76% |
Metabolism | Liver |
Elimination half-life | 34 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.003.714 |
Chemical and physical data | |
Formula | C13H14N2O3 |
Molar mass | 246.266 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant,[2] but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.